Business
Quanterix Announces New Agreements with Lilly to Advance Alzheimer’s Disease Diagnosis and Treatment
License agreement provides Quanterix access to Lilly’s P-tau217 antibody technology, creating pathways for plasma-based biomarkers for use in Alzheimer’s
About this update from Quanterix Corporation
[{"type":"text","content":"\nLicense agreement provides Quanterix access to Lilly’s P-tau217 antibody technology, creating pathways for plasma-based biomarkers for use in Alzheimer’s disease;\n\nEstablishes framework for future collaboration and supports development of Quanterix tests to advance diagnosing and treating life-threatening diseases\n\n BILLERICA, Mass.--(BUSINESS WIRE)--\nQuanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced it has entered into a collaboration with Eli Lilly and Company (Lilly) to advance the diagnosis, monitoring and treatment of Alzheimer’s disease. As part of the collaboration, Quanterix will receive a non-exclusive, world-wide license to Lilly’s proprietary P-tau217 antibody technology for potential near-term use in research use only products and services, and future in vitro diagnostic applications. The parties have also entered into a collaboration agreement, which establishes a framework for future projects focused on the development of Simoa® immunoassays. As part of this agreement, Lilly will fund $11 million of development with the Quanterix Accelerator group this year. The other financial terms were not disclosed.\n\nThese new agreements represent a commitment to advance blood-based biomarkers into routine clinical use. Plasma biomarkers have recently emerged as potential tools to speed clinical trial enrollment, improve clinical trial outcomes, eliminate the invasive techniques required to monitor drug efficacy and lower clinical trial costs. The initial collaboration under the agreements is expected to be focused on P-tau217, a blood-based biomarker that has shown diagnostic promise for early Alzheimer’s detection.\n\nFor Alzheimer’s disease, current diagnostic testing techniques, including PET imaging and lumbar punctures, are often difficult to obtain, more invasive and late. Both Quanterix and Lilly see the compelling value of plasma-based diagnostic tools to broaden access to testing, facilitate earlier Alzheimer’s disease diagnosis, identify candidates for emerging therapeutics and monitor disease progression with a simple blood test. These tests can help address the urgent need of patients, their families, physicians and the broader healthcare system.\n\n“We’re thrilled to collaborate with Lilly in developing innovative diag...